We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
12 June 2019
In Bayer v Apotex; Bayer v Teva,(1) the Federal Court ordered that common validity issues in actions relating to Bayer's rivaroxaban (Xarelto) against Apotex and Teva will be heard concurrently. Bayer objected to the concurrent hearing, arguing that consolidating the trials would constitute a joinder of actions and thus be prohibited by Section 6.02 of the Patented Medicines (Notice of Compliance) (PMNOC) Regulations. Prothonotary Tabib concluded that the application of Section 6.02 is limited to the joinder of actions as a whole and does not prohibit the common trial of an action. Relying on Biogen v Taro,(2) which arose in similar circumstances, she held that the common trial of issues in complex cases under the PMNOC Regulations "constitutes the most efficient use of the Court and the parties' time and resources".
In Genentech v Celltrion Healthcare,(3) the Federal Court refused to allow the plaintiffs to name additional Teva parties as further defendants in three actions relating to Celltrion's Herzuma, a trastuzumab biosimilar of Roche's Herceptin. The court reasoned that only 'second persons' may be named as defendants in actions under the PMNOC Regulations. The court left open the possibility that a 'second person' could include someone other than the person who filed the regulatory submission. However, the plaintiffs did not plead "sufficient material facts that if proven would enable the Court to make a finding that [Celltrion] was an agent, acting as a nominal second person, directed and controlled by the [Teva parties]". However, the court allowed the plaintiffs to amend the pleadings to claim that Celltrion would infringe the patents at issue by common design or acting in concert with the Teva parties.
For further information on this topic please contact Katie Lee or Urszula Wojtyra at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (firstname.lastname@example.org or email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
(1) 2019 FC 191.
(3) 2019 FC 293.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.